ImmunoDeficiency and ECMO for Acute respiratory failure
This study will provide, for the first time, detailed descriptive data on the characteristics, the complication and the outcome of adult’s immunocompromised patients receiving ECMO for ARDS. This study is closed
ECMO to rescue Lung Injury in severe ARDS
Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, Da Silva D, Zafrani L, Tirot P, Veber B, Maury E, Levy B, Cohen Y, Richard C, Kalfon P, Bouadma L, Mehdaoui H, Beduneau G, Lebreton G, Brochard L, Ferguson ND, Fan E, Slutsky AS, Brodie D, Mercat A; EOLIA Trial Group, REVA, and ECMONet. N Engl J Med. 2018 May 24;378(21):1965-1975.
EOLIA is a multicenter, international, randomized, controlled trial run by the REVA network and endorsed by the International ECMO Network. The study hypothesizes that ECMO, instituted early after the diagnosis of very severe ARDS (P:F < 80), would lower the morbidity and mortality associated with this syndrome.
Respiratory Failure Position Paper
The aim of this paper is to provide physicians, ECMO center directors and coordinators, hospital directors, health care organizations, regional, national and international policy makers a description of the optimal approach to organizing ECMO programs for acute respiratory failure in adult patients. Importantly, this will help ensure that ECMO is delivered safely and proficiently, such that future observational and randomized clinical trials assessing this technique may be performed by experienced centers under homogeneous and optimal conditions.
Cardiac Failure Position Paper
This position paper represents the expert opinion of an international group of physicians, ECMO specialists and allied health-care workers who have expertise relevant to the mechanical circulatory support used to treat patients with severe cardiac failure. The aim of this paper is to provide clinicians, ECMO center directors and coordinators, hospital administrators, healthcare organizations, and regional, national, and international policy makers a consensus approach to the organization of ECMO programs for cardiac failure and cardiac arrest in adults.
ECCO2R Position paper
This position paper represents the expert opinion of an international group of physicians and allied health-care professionals who have expertise relevant to the use of extracorporeal CO2 removal (ECCO2R) in clinical trials and practice. It will provide clinicians, ECCO2R providers, policy makers and clinical researchers with a concise summary of the technology and its use in research and clinical practice. This information informs a summary of recommendations for the use of ECCO2R and areas where there is a requirement for further study.